Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate, at steady-state, the systemic exposure and the lung
deposition of B17MP (active metabolite of BDP) as AUC0-12h,ss and Cmax,ss, after inhalation
of BDP (Clenil® Modulite®) with the AeroChamber Plus™ spacer device or with the Volumatic™
spacer device without or with charcoal block.